You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial

Article info

Article menu

This article has a correction. Please see:

XML
Immunotherapy biomarkers
Original research
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial

Authors

  • Xin Huang Gynecologic Oncololgy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaKey State Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Minjun He Gynecologic Oncololgy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaKey State Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Hongyu Peng Gynecologic Oncololgy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaKey State Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Chongjie Tong Gynecologic Oncololgy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaKey State Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Zhimin Liu Gynecologic Oncololgy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaKey State Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Xiaolong Zhang Key State Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, ChinaCenter for Bioinformatics, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Yang Shao Nanjing Geneseeq Technology Inc, Nanjing, ChinaSchool of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China PubMed articlesGoogle scholar articles
  • Dongqin Zhu Nanjing Geneseeq Technology Inc, Nanjing, China PubMed articlesGoogle scholar articles
  • Junli Zhang Nanjing Geneseeq Technology Inc, Nanjing, China PubMed articlesGoogle scholar articles
  • Jiani C Yin Nanjing Geneseeq Technology Inc, Nanjing, China PubMed articlesGoogle scholar articles
  • Fan Yang Gynecologic Oncololgy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaKey State Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Chunyan Lan Gynecologic Oncololgy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaKey State Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles

Citation

Huang X, He M, Peng H, et al
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial
Journal for ImmunoTherapy of Cancer 2021;9:e002223. doi: 10.1136/jitc-2020-002223
Online issue publication 
April 05, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.